Oral Aroxbutynin, Atomoxetine Combination Shows Promise in Reducing OSA Severity
CHICAGO – A 26-week study presented at the CHEST Annual Meeting this week indicates a combination of oral aroxbutynin and atomoxetine significantly lowered obstructive sleep apnea (OSA) severity in patients. Researchers reported improvements in apnea-hypopnea index (AHI) scores,suggesting a potential new therapeutic avenue for the millions affected by the condition.
Obstructive sleep apnea, a common disorder characterized by repeated interruptions in breathing during sleep, impacts an estimated 22 million Americans, often leading to daytime fatigue, cardiovascular problems, and reduced quality of life. Current treatments primarily involve continuous positive airway pressure (CPAP) therapy, which many patients find tough to adhere to. This study offers a glimpse of a possibly more tolerable pharmacological approach. The findings could reshape OSA management, offering a viable alternative or adjunct to existing therapies, and prompting further investigation into the underlying mechanisms driving these improvements.
The study evaluated the efficacy of the drug combination over a 26-week period. Specific AHI reduction data and patient demographics were not promptly available in the presented abstract.
researchers disclosed that Dr. Cronin has employment with Apnimed, and Dr. strollo has an advisory committee membership relationship with the same company.
The research was presented at the CHEST Annual Meeting, held October 19-22, 2025, in Chicago.
